Drugs / tenofovir alafenamide/emtricitabine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT05159531 | May → Jun 2023 | HIV infectious disease | Unity Health Toronto | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tenofovir alafenamide/emtricitabine | “HIV pre-exposure prophylaxis (PrEP) using regular oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) or tenofovir alafenamide/emtricitabine (TAF/FTC) is an effective...” NCT05159531 ↗ |
| Route | Oral | “daily oral TAF/FTC PrEP” NCT05159531 ↗ |